Core Viewpoint - The company plans to invest 20 million yuan in Zhuiyuan Medical Technology (Shanghai) Co., Ltd., acquiring a 9.0909% stake, aiming to enhance its business in the orthopedic field [1] Group 1: Investment Details - The investment amount is 20 million yuan, which will be used to increase the company's stake in Zhuiyuan Medical [1] - After the transaction, the company will hold a 9.0909% equity interest in Zhuiyuan Medical [1] Group 2: Strategic Goals - The company is focusing on strengthening its research and strategic layout in the orthopedic sector [1] - The investment aims to expand the company's business and enhance its comprehensive competitiveness and influence [1] - The target company's core team possesses significant technical expertise and innovative research capabilities, aligning with the company's existing business areas [1] Group 3: Expected Outcomes - The collaboration is expected to drive innovation and reform in orthopedic clinical treatment solutions [1] - The investment is intended to maximize shareholder value and enhance the overall company value [1]

Core Viewpoint - The company plans to invest 20 million yuan in Zuiyuan Medical Technology (Shanghai) Co., Ltd., acquiring a 9.0909% stake, aiming to enhance its business in the orthopedic field [1] Group 1: Investment Details - The investment amount is 20 million yuan [1] - After the investment, the company will hold a 9.0909% equity stake in Zuiyuan Medical [1] Group 2: Strategic Goals - The company is focusing on strengthening research and strategic layout in the orthopedic field [1] - The investment aims to expand the company's business and enhance its comprehensive competitiveness and influence [1] - The target company's core team possesses significant technical expertise and innovative research capabilities, aligning with the company's existing business areas [1]

Group 1 - The company, Aibo Medical, has invested in Super Eye Technology (Beijing) Co., Ltd. through an associated fund, although its shareholding is relatively small [2] - Aibo Medical will continue to monitor investment opportunities in the ophthalmology and related technology sectors [2]

Group 1 - The core event is the listing ceremony of Zhejiang Haiseng Medical Equipment Co., Ltd. on the Beijing Stock Exchange, scheduled for February 12, 2026, from 09:00 to 09:30, with a live broadcast of the entire event [1][3] - Zhejiang Haiseng Medical Equipment Co., Ltd. was established in 2000 and specializes in the research, production, and sales of anesthesia and monitoring medical devices, serving global clinical needs in various departments such as anesthesia, ICU, and emergency [3] - The company is recognized as one of the early technology-driven manufacturers in China focusing on anesthesia and monitoring medical consumables and equipment, positioning itself as a leading enterprise in this niche market [3] Group 2 - The listing ceremony will include several segments: introduction of guests, speeches by leaders, ringing the listing bell, and a group photo session with guests [3]

Group 1 - The company plans to implement an equity incentive plan at an appropriate time, aligning with its long-term strategic planning and short-term development needs [2] - The company will strictly adhere to relevant laws and regulations regarding information disclosure obligations [2]

Group 1 - The company has established a unified financial system prior to its listing, promoting the integration of financial and business data [2] - The company is implementing vertical financial management, business planning (BP), and centralized fund management [2] - The company will continue to optimize its financial digital processes, enhancing system integration and compliance efficiency [2] Group 2 - The company aims to further improve its overall management level to efficiently match its business development [2]

Group 1 - The company focuses on its core business while continuously monitoring and exploring new technologies and markets [2] - The company aims to expand its layout in the healthcare sector [2]

Core Viewpoint - Aibo Medical emphasizes that its stock price fluctuations in the secondary market are influenced by multiple factors, including macroeconomic conditions, industry cycles, and market sentiment, while the company aims to enhance its value through various means and effectively return value to shareholders [2] Group 1: Company Strategy - The company has established a good reputation among doctors and patients for its multiple artificial lens products, which are backed by outstanding technological advantages [2] - Aibo Medical plans to actively seize market opportunities to continuously increase its market share [2]

Group 1 - The core viewpoint of the article is that Microelectrophysiology announced its projected financial performance for 2025, indicating a positive growth trajectory in revenue and net profit [2] - The company expects to achieve an operating revenue of 464.53 million yuan in 2025, representing a year-on-year growth of 12.43% [2] - The net profit attributable to the parent company is projected to be 51.15 million yuan [2]

Core Viewpoint - Aibo Medical has a strong market share and leading position in the ophthalmic surgery and myopia prevention market in China, with a rapidly growing vision care business and plans to expand into high-comfort, functional consumer products [1] Group 1 - The company has a high market share in the ophthalmic surgery and myopia prevention market in China [1] - The vision care business is currently in a rapid growth phase [1] - The company is accelerating its expansion into high-comfort and functional consumer product markets [1]